Par Pharmaceutical Cos., Inc. (PRX) Tops Q3 EPS by 1c, Sales Miss Expectations
Tweet
Share
E-mailGet Alerts PRX Hot Sheet
Join SI Premium – FREE
Par Pharmaceutical Cos., Inc. (NYSE: PRX) reported Q3 non-GAAP EPS of $0.74, $0.01 better than the analyst estimate of $0.73. Revenue for the quarter came in at $215.4 million versus the consensus estimate of $309.97 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance
- Carnival Corp. (CCL) Tops Q3 EPS by 8c
- ConAgra Brands (CAG) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
